CA2998042C - Dactinomycin compositions and methods for the treatment of acute myeloid leukemia - Google Patents

Dactinomycin compositions and methods for the treatment of acute myeloid leukemia Download PDF

Info

Publication number
CA2998042C
CA2998042C CA2998042A CA2998042A CA2998042C CA 2998042 C CA2998042 C CA 2998042C CA 2998042 A CA2998042 A CA 2998042A CA 2998042 A CA2998042 A CA 2998042A CA 2998042 C CA2998042 C CA 2998042C
Authority
CA
Canada
Prior art keywords
composition
dactinomycin
administration
disclosure
therapeutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2998042A
Other languages
English (en)
French (fr)
Other versions
CA2998042A1 (en
Inventor
Brunangelo Falini
Maria Martelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2998042A1 publication Critical patent/CA2998042A1/en
Application granted granted Critical
Publication of CA2998042C publication Critical patent/CA2998042C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2998042A 2015-09-14 2016-09-13 Dactinomycin compositions and methods for the treatment of acute myeloid leukemia Active CA2998042C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562218433P 2015-09-14 2015-09-14
US62/218,433 2015-09-14
PCT/EP2016/071599 WO2017046108A1 (en) 2015-09-14 2016-09-13 Dactinomycin compositions and methods for the treatment of acute myeloid leukemia

Publications (2)

Publication Number Publication Date
CA2998042A1 CA2998042A1 (en) 2017-03-23
CA2998042C true CA2998042C (en) 2022-07-05

Family

ID=56896582

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2998042A Active CA2998042C (en) 2015-09-14 2016-09-13 Dactinomycin compositions and methods for the treatment of acute myeloid leukemia

Country Status (7)

Country Link
US (2) US10335416B2 (https=)
EP (1) EP3349759B1 (https=)
JP (1) JP7001599B2 (https=)
AU (1) AU2016324920B2 (https=)
CA (1) CA2998042C (https=)
ES (1) ES2809805T3 (https=)
WO (1) WO2017046108A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016324920B2 (en) 2015-09-14 2022-03-03 Brunangelo Falini Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
CA3031691A1 (en) 2016-09-13 2018-03-22 Rasna Research Inc. Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
JP2022503792A (ja) * 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
EA202290154A1 (ru) 2019-06-27 2022-03-29 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты
KR102886965B1 (ko) * 2022-02-28 2025-11-17 한국유나이티드제약 주식회사 향상된 용해도를 가지는 닥티노마이신 함유 약학조성물의 제조방법
WO2024124199A1 (en) * 2022-12-10 2024-06-13 Aptose Biosciences Inc. Methods for treating patients with hematologic malignancies
CN116942834B (zh) * 2023-06-12 2024-04-05 新乡医学院 包含核仁应激诱导剂的抗肿瘤药物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB0223341D0 (en) 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
EP2397149A1 (en) 2010-06-17 2011-12-21 Hil-Invent Ges.M.B.H. Pharmaceutical preparation comprising actinomycin D for the treatment of B-CLL in patients having del(17p)
WO2015101618A1 (en) * 2013-12-30 2015-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia
AU2016324920B2 (en) 2015-09-14 2022-03-03 Brunangelo Falini Dactinomycin compositions and methods for the treatment of acute myeloid leukemia

Also Published As

Publication number Publication date
US20190314380A1 (en) 2019-10-17
JP7001599B2 (ja) 2022-01-19
CA2998042A1 (en) 2017-03-23
WO2017046108A1 (en) 2017-03-23
ES2809805T3 (es) 2021-03-05
AU2016324920B2 (en) 2022-03-03
US10335416B2 (en) 2019-07-02
EP3349759A1 (en) 2018-07-25
US20180207168A1 (en) 2018-07-26
JP2018526460A (ja) 2018-09-13
EP3349759B1 (en) 2020-05-20
US11337983B2 (en) 2022-05-24
AU2016324920A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
US11337983B2 (en) Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
CN103501785B (zh) 用于治疗脑肿瘤的csf-1r抑制剂
US12370178B2 (en) Tinostamustine for use in the treatment of t-cell prolymphocytic leukaemia
AU2002311985B2 (en) Methods for inhibiting angiogenesis
KR102613106B1 (ko) Ｂ―세포 악성종양의 치료를 위한 세르둘라티닙
AU2002311985A1 (en) Methods for inhibiting angiogenesis
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
JP2021505571A (ja) 末梢ｔ細胞リンパ腫および皮膚ｔ細胞リンパ腫を治療するための組成物および方法
EP3407887A1 (en) Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor
US20040048808A1 (en) Methods for inhibiting angiogenesis
US20240025959A1 (en) Beclin 2 and uses thereof for treating cancer and neurodegenerative diseases
CN116019810B (zh) FoXO1抑制剂在制备淋巴瘤预防和治疗药物中的应用
CN1655801A (zh) 在化疗期间保护内皮和上皮细胞的方法
AU2024238523A1 (en) Pharmaceutical composition and use thereof
CA3286442A1 (en) Pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210903

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240906

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240906

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240906

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909